MiMedx Group, Inc. announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors.

Ms. Olson currently serves as a board member for two other public companies, Telix Pharmaceuticals and Castle Biosciences, and a privately held growth-stage company, Langham Logistics. She previously held CEO, president, and senior leadership positions in the U.S. and Europe at multiple international Fortune 100 healthcare companies, including Cardinal Health, Roche, and Eli Lilly. Ms. Puhy has previously held board positions at Abiomed, Azenta, Eaton Vance, Reebok, and other privately held companies.

She has also held several executive leadership positions, including CFO and EVP, COO of Dana-Farber Cancer Institute and EVP, CFO of New England Medical Center (now Tufts Medical Center).